Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $53.14 Average PT from Brokerages
Shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) have received a consensus recommendation of “Buy” from the ...
AlphaQuest LLC Raises Stock Position in Immunome, Inc. (NASDAQ:IMNM)
AlphaQuest LLC grew its stake in shares of Immunome, Inc. (NASDAQ:IMNM – Free Report) by 786,700.0% during the 4th quarter, ...
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...
MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript
Q4 2024 Results Conference Call March 19, 2025 8:30 AM ETCompany ParticipantsDan Ferry - IR, LifeSci AdvisorsOfer Gonen - ...
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcersExpanded strategic research collaborations with industry ...
GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...
Kalaris Announces Closing of Merger with AlloVir
Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...